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Abstract
P2Y receptors are G protein coupled receptors that respond to extracellular nucleotides to promote a multitude of
signaling events. Our laboratory has purified several P2Y receptors with the goal of providing molecular insight into
their: (1) ligand binding properties, (2) G protein signaling selectivities, and (3) regulation by RGS proteins and other
signaling cohorts. The human P2Y1 receptor and the human P2Y12 receptor, both of which are intimately involved in
ADP-mediated platelet aggregation, were purified to near homogeneity and studied in detail. After high-level expression
from recombinant baculovirus infection of Sf9 insect cells, approximately 50% of the receptors were successfully
extracted with digitonin. Purification of nearly homogeneous epitope-tagged P2Y receptor was achieved using metal-
affinity chromatography followed by other traditional chromatographic steps. Yields of purified P2Y receptors range from
10 to 100 mg/l of infected cells. Once purified, the receptors were reconstituted in model lipid vesicles along with their
cognate G proteins to assess receptor function. Agonist-promoted increases in steady-state GTPase assays demonstrated
the functional activity of the reconstituted purified receptor. We have utilized this reconstitution system to assess the
action of various nucleotide agonists and antagonists, the relative G protein selectivity, and the influence of other
proteins, such as phospholipase C, on P2Y receptor-promoted signaling. Furthermore, we have identified the RGS
expression profile of platelets and have begun to assess the action of these RGS proteins in a reconstituted P2Y receptor/G
protein platelet model.
Abbreviations: 2MeSADP – 2-methylthio-ADP; CHAPS–3-(3-cholamidopropyl)dimethyl-ammonio-1-propanesulfonate;
DDM–n-dodecyl-b-D-maltose; GAP–GTPase activating protein; GDI–guanine nucleotide dissociation inhibitor; GEF–
guanine nucleotide exchange factor; GPCR – G protein coupled receptor; Ni-NTA –nickel-nitrilotriacetic acid;
octylglucoside – n-octyl-b-D-glucopyranoside; PLC–phospholipase C; RGS–regulator of G protein signaling
Introduction
G protein-coupled receptors (GPCRs) represent one of
the largest targets for therapeutic development. The P2Y
receptor family of GPCRs are heptahelical transmem-
brane proteins that allow extracellular signals, in the
form of nucleotides, to initiate intracellular signaling
cascades that result in a wide range of physiological
responses [1–3]. P2Y receptors have been subdivided into
two groups based on sequence homology and G protein
selectivity. Subtypes of the P2Y1-like family, comprised of
the P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11 receptors, all
couple to Gaq to activate phospholipase C (PLC). These
five receptors were the first P2Y receptors cloned and were
illustrated to be activated by ADP (P2Y1), ATP and UTP
(P2Y2), UTP (P2Y4), UDP (P2Y6), and ATP (P2Y11).
Existence of a Gi/adenylyl cyclase-coupled receptor for
ADP was initially reported by Cooper and Rodbell [4] in
1979, but molecular identification of this Gi-coupled P2Y
receptor remained elusive for two decades. However, the
P2Y12 receptor was ultimately cloned in 2001 and a P2Y12-
like subfamily of P2Y receptors exists that includes the ADP-
activated P2Y12 receptor, the ADP-activated P2Y13 receptor,
and the nucleotide-sugar-activated P2Y14 receptor [5–10].
Unambiguous delineation of the ligand selectivity of
P2Y receptors is difficult due to the nature of nucleotide-
promoted signaling. All cell systems used to study P2Y
receptor-mediated signaling release nucleotides basally
and/or after mechanical stimulation. Moreover, cell surface
expression of enzymes that metabolize or interconvert
nucleotides confounds the interpretation of results obtained
with exogenously presented nucleotides. Although radio-
ligand binding assays provide useful means to study P2Y
receptor binding properties in ways that circumvent some
of these problems, lack of high-affinity, stable, and
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vented the development of such direct assays.
A recent goal ofourlaboratoryhas beenpurificationofthe
P2Y receptor subtypes to near homogeneity. These purified
receptors allow unequivocal determination of ligand binding
selectivities and also provide a well controlled system to
study both G protein selectivity and influences of other
proteins on the signaling activities of P2Y receptors. Thus,
recombinant P2Y receptors are solubilized in detergent,
purified, and reconstituted into model phospholipid vesicles
with heterotrimeric G proteins. Our data to date indicate
maintenance of the native structure and signaling properties
ofthetwoADP-activatedreceptorsofplatelets,theP2Y1 and
P2Y12 receptors, when studied in purified form. This
approach was initially applied by Elliot Ross and coworkers
to address questions of the molecular mechanism(s) of
b-adrenergic receptor/G protein interaction [11]. Detergent-
solubilized b-adrenergic receptors maintained ligand affin-
ities equivalent to those of the natively expressed receptor,
and hormone-promoted activation of G proteins was
observed when these signaling partners were combined by
reconstitution in model phospholipid vesicles. This ap-
proach has been greatly simplified with the advent of
molecular techniques designed to epitope-tag proteins and
through the use of high-level expression systems. Applica-
tion of this technology to purinergic receptors provides a
reliable and precise means to study the ligand and G protein
selectivity of P2Y receptors in an environment independent
of nucleotide interconversion, release, or metabolism.
Our lab has attempted to purify several P2Y receptors,
including the human P2Y1,h u m a nP 2 Y 2, human P2Y2 fused
to its cognate G protein Gaq (P2Y2-Gq), human P2Y12,a n d
an avian P2Y receptor [12]. The avian P2Y receptor is
unique among all species members of the P2Y family in that
it couples equally well to both Gaq and Gai, essentially
encompassing the properties of the two mammalian sub-
families, the P2Y1-like Gq-coupled and the P2Y12-like
Gi-coupled families [12, 13]. Among other physiological
actions, the P2Y2 receptor is critical in lung airway phy-
siology and is a current target for the development of cystic
fibrosis therapeutics [14, 15]. The P2Y1 receptor and the
P2Y12 receptor are mediators of the physiological action of
ADP in platelets, and activation of both receptors is required
to initiate and sustain platelet aggregation [16–18]. A clin-
ically important drug clopidogrel targets the P2Y12 receptor,
and many more therapeutic agents currently are in develop-
ment targeting both the P2Y1 and P2Y12 receptors [19].
Receptor expression and solubilization
To allow purification of sufficient quantities of P2Y recep-
tors, a baculovirus/Sf9 (Spodoptera frugaperda) insect cell
system was used, which provides high-level expression of
post-translationally modified proteins. Receptor genes
were subcloned into either PVL1393 (for the P2Y1, P2Y2,
P2Y2-Gq and the avian P2Y clones), which contains a C-
terminal hexahistidine epitope-tag and an N-terminal
FLAG epitope-tag, or pFastbac HTb (for the P2Y12 clone),
which contains only an N-terminal hexahistidine epitope
tag. High-titer receptor-expressing viral stocks were pro-
duced and used for infections of Sf9 insect cells.
Following centrifugation and subsequent lysis of cells,
receptor-containing membranes were collected. The
pelleted membranes were resuspended in digitonin-con-
taining extraction buffer to a concentration of 3–5 mg of
protein/ml, and the extraction was carried out by gentle
agitation for 1 h at 4 -C. Solubilized membrane proteins
were recovered by collection of the supernatant follow-
ing centrifugation at 100,000 g for 1 h. The use of 1%
digitonin resulted in extraction of nearly 50% of receptors
from the membrane for the P2Y12 receptor (Figure 1) as
well as the P2Y1 and the P2Y2 receptors (data not shown).
Under identical extraction conditions, neither the avian
P2Y receptor nor the P2Y2- G qf u s i o np r o t e i nw a s
solubilized from the membrane (Figure 1). Other deter-
gents, such as 1% DDM (Figure 1 for avian P2Y), CHAPS,
or octylglucoside (data not shown) were tested for their
capacity to extract the receptors. However, both the avian
P2Y receptor and P2Y2-Gq fusion protein remained
insoluble in these conditions. The cause of this insolubility
remains unclear. One possibility is the proteins are
misfolded. The co-expression of other protein(s) may be
required to stabilize these otherwise insoluble receptors for
proper processing and expression at the plasma membrane.
Receptor purification
Solubilized P2Y1, P2Y2, and P2Y12 receptors were purified
utilizing the hexahistidine tag, which binds with high
Figure 1. Immunoblot analysis of extraction of recombinant P2Y
receptors with detergent. Recombinant P2Y receptors tagged with His-6
(P2Y12 and avian P2Y) or FLAG (P2Y2-aq) epitopes were extracted from
Sf9 insect cell plasma membranes with the indicated detergent and at
protein concentrations of 1, 2, or 5 mg/ml. Extractions were carried out at
4 -C for 1 h followed by high-speed centrifugation. Avian P2Y receptor
(P2Ya), Total (T), high speed supernatant extract (E).
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2+. Thus, one-step
purification of the solubilized receptor is achieved follow-
ing incubation with Ni-NTA resin (for greater detail of
receptor purification, see Bodor et al. [20] and Waldo et al.
[21]). This single step provides active receptor that is
functional in subsequent reconstitution assays. However,
the level of purity is low (Figure 2a, lane 3). Further
chromatographic steps involving ion exchange and/or gel
filtration resulted in near homogeneous receptor prepara-
tions as seen for the P2Y1, P2Y2, and P2Y12 receptors in
Figures 2 and 3. Furthermore, all three receptors were
expressed as glycosylated proteins as determined by a
decrease in apparent molecular mass following treatment
with N-glycosidase F as shown in Figure 3 for the P2Y2
receptor and as shown previously for the P2Y1 and P2Y12
receptors [20, 21]. Many GPCRs contain at least one
consensus site for N-linked glycosylation that may confer
some functional properties. For example, glycosylation of
thrombin receptors appears to be necessary for thrombin
binding whereas glycosylation of the b2-adrenergic recep-
tor has no effect on ligand binding but is necessary for
normal G protein coupling [22, 23]. The availability of an
excellent radioligand binding assay for P2Y1 receptors
permits quantification of functional P2Y1 receptor binding
sites at each step of purification using the radiolabeled
antagonist, [
3H]MRS2279 [24]. As reported earlier, the
P2Y1 receptor was purified approximately 1000-fold,
resulting in a specific activity of approximately 3.0 nmol/mg
[21]. Qualitative assessment of the P2Y2 and P2Y12
receptor purifications suggest similar fold increases in
purity. Yields of purified P2Y receptors typically range
from 10 to 100 mg/l of infected cells. Our laboratory also
routinely purifies Ga-subunits [25], Gbg-subunits [25], and
PLC-b isozymes [26] after expression of recombinant
proteins from baculoviruses in Sf9 insect cells.
Functional reconstitution of purified receptors
Retention of native signaling activities has been confirmed
with several of the purified P2Y receptors after reconsti-
tution with heterotrimeric G proteins in model phospholip-
id vesicles. The initial step in forming protein-containing
phospholipid vesicles is the preparation of detergent/
phospholipid mixed micelles. The type of lipids used and
their relative amounts is critical for proper membrane
fusion, protein incorporation, and orientation of integral-
membrane proteins (for a detailed review, see Racker
[27]). Phosphatidylethanolamine, phosphatidylserine, and
cholesteryl hemisuccinate, which all have been used
previously in successful reconstitution experiments with
GPCRs, are dried and then resuspended in deoxycholate-
containing buffer. This preparation is then combined with
15 pmol of purified receptor, 50 pmol of Ga, and 150 pmol
of Gb1g2 and immediately loaded onto a G-50 Sephadex
column. The void volume, which contains the vesicles, is
eluted and collected. Although G-50 Sephadex resin does
not separate the formed vesicles from free proteins of the
molecular sizes used in these studies, contamination of
vesicles with free protein is inconsequential. Alternatively,
we have prepared vesicles with either an ACA-34 column
or Sephacryl S-300 resin, both of which readily separate
vesicles from free proteins.
Activities of purified P2Y receptors
To assess the activity of P2Y receptor-containing phos-
pholipid vesicles, agonist-promoted receptor-mediated
Figure 2. Purified P2Y12 and P2Y1 receptors. (a) Following solubiliza-
tion of P2Y12 expressing Sf9 membranes with 1% digitonin, the
solubilized fraction was batch incubated with Ni-NTA and then eluted
with buffer containing 150 mM imidazole. This eluate was then loaded
onto a 1-ml HT Q ion exchange column and protein eluted by a
gradient of NaCl. The receptor was further purified by loading the HT
Q eluate onto a 1-ml Ni
2+-charged HT metal chelate (HTMC) column.
Receptor was eluted by an imidazole gradient and concentrated using a
Centricon YM-30 centrifugal filter device. Load (LD), flow through (FT).
(b) Protein-stained SDS-PAGE gel of the purified P2Y1 receptor following
purification as detailed by Waldo et al. [21].
Figure 3. SDS-PAGE and immunoblot analysis of purified recombinant
human P2Y2 receptor. Recombinant human P2Y2 receptor tagged with
His-6 and FLAG epitopes was purified as described previously for the
P2Y1 and P2Y12 receptors [20, 21]. Purified P2Y2 receptor was treated
with N-glycosidase F (+) or untreated (j) and subjected to SDS-PAGE
analysis. The resulting gel was stained with Coomassie blue or was
transferred to nitrocellulose and immunoblotted with anti-FLAG antibody.
The N-glycosidase F is identified (P) in the Coomassie-stained gel.
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GTPase activity of Ga subunits depends on both the rate of
GTP hydrolysis and the rate of guanine nucleotide
exchange (Figure 4). Typically, guanine nucleotide ex-
change by heterotrimeric G proteins is rate-limiting, and
increases in GTP catalysis by the presence of GTPase
activating proteins (GAPs), such as RGS proteins, results
in only small increases in measured GTPase activity under
basal conditions. This is particularly true for steady-state
GTPase measurements with members of the Gaq family
that bind GDP tightly in the basal state. However, in the
presence of robust agonist-promoted guanine nucleotide
exchange, GTP hydrolysis becomes rate-limiting and
remarkably large increases in GTPase activity are observed
due to the catalytic activity of RGS proteins or other GAPs
such as PLC-b isozymes. Steady-state GTPase activity of a
Ga subunit under the concerted regulation of a GPCR and
an RGS protein is the summation of multiple steps in a
complex regulatory cycle [28]. In its simplest application,
this system provides an optimal means to assess agonist or
antagonist activity of nucleotides and other molecules at
P2Y receptors. As an extension, this is a powerful system
to establish G protein selectivities of a given P2Y receptor,
as well as to elucidate the regulatory activities of other
molecules central to G protein signaling.
To assess steady-state GTP hydrolysis, GTP labeled at
the g-phosphate with
32P is incubated with vesicles
reconstituted with P2Y receptors and heterotrimeric G
proteins. Liberated [
32P]Pi is then quantified as described
previously to determine basal activity and activities
promoted by P2Y receptor activation and/or stimulation
of GTPase activity by RGS proteins or effectors such as
PLC-b, which are GAPs [20, 21]. As shown in previous
publications from our laboratory, both the purified P2Y1
and the P2Y12 receptors maintain activities expected based
on previous studies of the native receptors [20, 21]. Briefly,
2MeSADP was the most potent agonist tested in recon-
stitutions with purified P2Y1 receptor and Gaqb1g2, while
ATP was a partial agonist. Both RGS4 and PLC-b were
effective GAPs in the P2Y1 receptor/Gq reconstitution
experiments [21]. P2Y12 reconstitution experiments also
revealed 2MeSADP as the most potent agonist tested while
the cognate P2Y12 agonist, ADP, was three orders of
magnitude less potent. ATP exhibited no agonist activity
but inhibited the action of 2MeSADP at the P2Y12 recep-
tor. Following reconstitution with Gb1g2 and Ga-subunits
of the Gi and Gq families, we demonstrated selective cou-
pling of the P2Y12 receptor to Gai2 [20].
In contrast to the robust activities observed with purified
P2Y1 and P2Y12 receptors, no UTP or ATP promoted
activity was observed with the purified P2Y2 receptor
reconstituted in proteoliposomes with Gaqb1g2 (Figure 5a).
Various detergents were examined to determine if the
nature of the detergent influenced the retention of activity
Figure 4. Schematic representation of the P2Y1- or P2Y12-activated G
protein cycle. Agonist activation of either the P2Y1 or the P2Y12 receptor
causes an increase in the rate of guanine nucleotide exchange on Gaq or
Gai, respectively, whereby GTP replaces GDP, creating the active species
Ga-GTP. The signaling pathway is turned off by hydrolysis of bound GTP
to GDP by the G protein. GAPs, such as RGS proteins, or PLC-b in the
case of Gaq, augment the rate of GTP hydrolysis. Hence, two important
rate limiting steps exist in the signaling pathway: (1) the rate of guanine
nucleotide exchange (regulated by the agonist-activated receptor acting as
a GEF) and (2) the rate of GTP hydrolysis (regulated by GAPs).
Figure 5. P2Y2 receptor agonists do not promote steady-state GTP hydrolysis in proteoliposomes containing P2Y2 receptor/Gaqb1g2: Purified P2Y2
receptor, Gaq, and Gb1g2 were reconstituted in proteoliposomes. (a) Steady-state GTP hydrolysis was measured in proteoliposomes containing P2Y2
receptor extracted with the indicated detergent in the absence (j) or presence (+) of 100 nM RGS4 and 10 mM of the indicated agonist. (b) Steady-state
GTP hydrolysis was measured in proteoliposomes containing either purified P2Y1 receptor, P2Y2 receptor, or both incubated in the absence (j)o r
presence (+) of 100 nM RGS4 and 10 mM of the indicated nucleotide agonist.
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effective for extraction of the P2Y1 receptor and the P2Y12
receptor in active forms, both dodecyl maltoside and
sucrose monolaurate were used to solubilize active P2Y2
receptor but with little success (Figure 5a). To be certain
that inhibitory factors did not co-purify with the P2Y2
receptor, the P2Y1 and P2Y2 receptors were reconstituted
either independently or were co-reconstituted into vesicles
along with purified Gaq and Gb1g2. While the P2Y1
receptor maintained its activity in the presence of RGS4
and agonist when reconstituted alone or with the P2Y2
receptor, the P2Y2 receptor exhibited no activity under
either condition (Figure 5b). These results suggest that no
inhibitory components are co-purified in the P2Y2 receptor
preparation. The inactivity of the purified P2Y2 receptor is
puzzling. While purified under similar conditions to the
active purified P2Y1 and P2Y12 receptors, the P2Y2
receptor is unable to stimulate GTPase activity. Unfortu-
nately, a P2Y2 receptor-specific radioligand is not avail-
able to determine if the receptor is active when initially
expressed in the Sf9 insect cells or if binding activity is
lost subsequent to solubilization. Alternatively, the purified
receptor may be modified in such a way as to interfere with
G protein coupling or may be lacking a necessary binding
partner(s) to maintain activity.
Utility of purified receptor preparations
The successful purification and functional reconstitution of
P2Y receptors allows studies of P2Y signaling and its
regulation in a system free of nucleotide release, intercon-
version, or metabolism, which is critical in studies of
nucleotide-based agonists and antagonists. Indeed, we have
functionally reconstituted an entire P2Y receptor–G protein–
effector system by illustrating that an effector of the P2Y1
receptor, PLC-b1, acts as a GAP on Gaq in phospholipid
vesicles composed of the P2Y1 receptor and Gaqb1g2 [21].
P2Y1 and P2Y12 receptor-containing vesicles also have
been used to assess the action of RGS proteins in these
systems. For example, RGS4, a GAP for Ga-subunits of
the Gi and Gq families, and RGS2, a GAP primarily for
Gq, are nearly equivalent in action in the proteoliposomes
reconstituted with the P2Y1 receptor and Gaq (Figure 6a).
Furthermore, at a single concentration, both RGS4 and
RGS5 are nearly equivalent in stimulating GTP hydrolysis
in P2Y12/Gai2 reconstituted vesicles (Figure 6b). The
relative action of various other purified RGS proteins is
currently under investigation. Other components of G
protein signaling, including GDIs (guanine dissociation
inhibitors) and various Gbg dimer compositions, can be
studied in this reconstituted system. For example, Kimple
et al. [29] identified a GoLoco motif(s) in RGS12 and
RGS14 that inhibits the dissociation of GDP from members
of the Gi family of G proteins. Garrison and coworkers
[30–32] have demonstrated the impact of Gbg dimer
composition on receptor/Ga coupling. The application of
these and other proteins to this P2Y receptor-reconstitution
system will illuminate complexities of signaling related to
individual P2Y receptor subtypes.
RGS proteins in a reconstituted GPCR/G protein
platelet model
RGS proteins are classically defined as GTPase activating
proteins. However, RGS proteins likely play more complex
roles in GPCR signaling. In addition to their conserved
RGS box domain, members of a number of RGS
subfamilies contain multiple domains that allow protein–
protein interactions, potentially conferring to these proteins
activities in addition to their capacity to promote GTP
hydrolysis by Ga-subunits. For example, the aforemen-
tioned GoLoco domain, as well as PDZ and PTB domains
exist in RGS12 and RGS14, a GGL domain exists in
RGS6, 7, 9, and 11 that confers to these RGS proteins
Figure 6. Capacity of RGS proteins for stimulation of steady-state GTPase activity. (a) Purified P2Y1 receptor, Gaq, and Gb1g2 were reconstituted in
proteoliposomes. Steady-state GTP hydrolysis was measured in proteoliposomes incubated with 10 mM 2MeSADP and increasing concentrations of
either RGS2 (h) or RGS4 (r). (b) Purified P2Y12 receptor, Gai2, and Gb1g2 were reconstituted in proteoliposomes. Steady-state GTP hydrolysis was
measured in the absence or presence of 10 mM 2MeSADP, 100 nM hRGS4, or 100 nM hRGS5.
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DH/PH domain exists in the RGS protein p115RhoGEF
that confers activity as a guanine nucleotide exchange
factor for Rho (for an RGS review, see Neubig and
Siderovski [33]).
Because of the critical role both the P2Y1 and P2Y12
receptors play in platelets, we have identified which RGS
proteins are expressed in human platelets with the goal of
focusing on a subset of RGS proteins that may regulate
P2Y receptor/G protein coupling in the physiological
response to ADP. The apparent expression profile of RGS
proteins in platelets was determined using specific primers
designed to 26 different RGS proteins (for a comprehen-
sive list of RGS box-containing proteins, see Neubig and
Siderovski [33]). These primers then were used to screen
cDNA generated from human platelet mRNA. To control
for message potentially present from sources other then
platelets, we also utilized specific primers for TCRb and
CD45, both of which are expressed at high levels in other
blood cells such as T cells, B cells, and natural killer cells,
but are not expressed in platelets. Messages for RGS3,
RGS10, and RGS18 (Figure 7, note that not all RGS
proteins screened are shown) were identified in this screen
of human platelet mRNA. While the level of RGS6 appears
to only moderately exceed the negative controls, the
existence of RGS6 in platelets is bolstered by the high
level of Gb5 message, which is the necessary binding
cohort for RGS6 and other members of the R7 family of
RGS proteins (Figure 7). Previous reports also have
identified RGS1, RGS2, and RGS16 in platelets [34–36].
The message for these RGS proteins may be too low in our
platelet RNA sample, thus rendering them undetectable.
Intriguingly, most of the RGS proteins expressed in
platelets are members of the R4 family of RGS proteins,
and thus principally consist of an RGS domain with very
short amino- and carboxy-termini that lack any other
discernable motifs or domains. Several recent reports
suggest that these small RGS proteins confer receptor-
selectivity in G protein signaling. Indirect evidence was
initially reported by Wilkie and coworkers who observed
that RGS1, RGS4, and RGS16 differentially inhibited the
capacity of three different Gq-coupled receptors to promote
Ca
2+ signaling [37]. Recently, Bernstein et al. [38] showed
that RGS2 directly interacts with the 3rd intracellular loop
of the human M1-muscarinic receptor. Our reconstitution
model will enable us to examine the functional interaction
of this defined set of RGS proteins on P2Y1 and P2Y12
receptor-dependent signaling.
Conclusion
Despite high level expression of various P2Y receptors in
Sf9 insect cells, only a subset of these receptors proved to
be solubilized by detergents. Of the three receptors that
were successfully solubilized, only two were active upon
reconstitution with their cognate heterotrimeric G proteins.
The reason for the insolubility/inactivity of some receptors
is unknown. Analyses of the two active receptors, the P2Y1
and the P2Y12 receptors, have provided novel and
unequivocal insight into the signaling properties of these
receptors. Future studies of RGS proteins, GDIs and Gbg
dimers in our reconstitution systems should lead to further
delineation of the intricacies of P2Y signaling.
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